Cardiac repair with adult bone marrow-derived cells: the clinical evidence.
On the basis of strong evidence from animal studies, numerous clinical trials of cardiac repair with adult bone marrow-derived cells (BMC) have been completed. These relatively smaller studies employed different BMC types with highly variable numbers, routes, and timings of transplantation, and included patients with acute myocardial infarction (MI), chronic ischemic heart disease (IHD), as well as ischemic cardiomyopathy. Although the outcomes have been predictably disparate, analysis of pooled data indicates that BMC therapy in patients with acute MI and chronic IHD results in modest improvements in left ventricular function and infarct scar size without any increase in untoward effects. However, the precise mechanisms underlying these benefits remain to be ascertained, and the specific advantages of one BMC type over another remain to be determined. The long-term benefit and safety issues with different BMC types are currently being evaluated critically in larger randomized controlled trials with a view to applying this novel therapeutic strategy to broader patient populations. The purpose of this review is to summarize the available clinical evidence regarding the efficacy and safety of therapeutic cardiac repair with different types of adult BMCs, and to discuss the key variables that need optimization to further enhance the benefits of BMC therapy.
Dawn
Buddhadeb
B
Division of Cardiovascular Medicine and the Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky 40292, USA. buddha@louisville.edu
Abdel-Latif
Ahmed
A
Sanganalmath
Santosh K
SK
Flaherty
Michael P
MP
Zuba-Surma
Ewa K
EK
D000328:Adult; D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology*; D017690:Cell Transplantation; D018849:Controlled Clinical Trials as Topic; D006331:Heart Diseases / Q000628:therapy*; D006801:Humans; D012038:Regeneration